Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based generics giant Teva Pharmaceutical Industries has had good news to report after its abbreviated new drug application for a generic version of Ortho McNeil Pharmaceuticals' antibiotic Levaquin was granted final approval from the FDA.
Subscribe to our email newsletter
The abbreviated new drug application (ANDA) is for Levofloxacin tablets 750mg, the AB-rated generic equivalent of Ortho McNeil Pharmaceutical broad spectrum antibiotic.
As the first ANDA applicant to file an ANDA with a paragraph IV patent certification, Teva has been awarded 180 days of generic drug exclusivity for Levofloxacin tablets 750mg.
Shipment of this product will not commence at least until a decision in the pending patent litigation in the US District Court for the District of New Jersey is made.
In addition, Teva expects to receive final approval for its Levofloxacin tablets in the 250mg and 500mg strengths upon the earlier of either the expiration of another ANDA filer’s 180-day marketing exclusivity, or the expiration of the patent.